Genentech: Home

News & Features

		Strike Out Cancer This baseball season, Genentech is participating in the seventh annual Strike Out Cancer program in partnership with the San Francisco Giants and The Wellness Community.



		Breast Cancer FDA Application On July 6, 2010, Genentech announced it submitted a Biologics License Application to the FDA for an experimental medicine in advanced HER2-positive breast cancer.

SCIENTIFIC LEADERSHIP >> Genentech's scientists are some of the most prolific in the industry and in their fields.



DEVELOPMENT PIPELINE >> Genentech's pipeline continues to grow, with multiple promising projects in development.

On July 1, 2010, Genentech announced a second Phase III study of a Genentech medicine in ovarian cancer met its primary endpoint.

Genentech is committed to making sure price is not a barrier to access for patients.

View the latest global media releases from the Roche Group on Roche.com.